Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase Ib/II Study of APG-115 as a Monotherapy or in Combination With Pembrolizumab in Patients With Unresectable or Metastatic Melanomas or Advanced Solid Tumors

NCT03611868 is registered in ClinicalTrials.gov with Ascentage Pharma Group Inc. as lead sponsor.

NCT NCT03611868
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03611868 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase Ib/II Study of APG-115 as a Monotherapy or in Combination With Pembrolizumab in Patients With Unresectable or Metastatic Melanomas or Advanced Solid Tumors
Lead sponsor
Ascentage Pharma Group Inc.
Phase
Phase 1/2
Overall status
Active, not recruiting
Start date
August 29, 2018
Completion date
December 30, 2025
Enrollment
230 (estimated)
Sites
21

Conditions

As the registry lists them; a condition with its own page is linked.

cutaneous melanoma, malignant peripheral nerve sheath tumors (mpnst), mdm2 gene mutation, melanoma, mucosal melanoma, p53 mutation, unresectable or metastatic melanoma or advanced solid tumors, uveal melanoma